Sagent Pharmaceuticals Inc (SGNT.OQ) Quote| Reuters.com
Edition:
United States

Sagent Pharmaceuticals Inc (SGNT.OQ)

SGNT.OQ on NASDAQ Stock Exchange Global Select Market

15.02USD
24 Jun 2016
Change (% chg)

$-0.30 (-1.96%)
Prev Close
$15.32
Open
$14.70
Day's High
$15.10
Day's Low
$14.65
Volume
391,264
Avg. Vol
136,878
52-wk High
$26.40
52-wk Low
$10.62

SGNT.OQ

Chart for SGNT.OQ

About

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It... (more)

Overall

Beta: 1.39
Market Cap(Mil.): $493.24
Shares Outstanding(Mil.): 32.84
Dividend: --
Yield (%): --

Financials

  SGNT.OQ Industry Sector
P/E (TTM): -- 32.69 34.11
EPS (TTM): -0.76 -- --
ROI: -8.98 15.00 14.23
ROE: -9.58 16.08 15.46

BRIEF-Sagent Pharmaceuticals buys product portfolio from Teva Pharmaceutical

* Sagent Pharmaceuticals acquires product portfolio from Teva Pharmaceutical Industries Ltd

Jun 16 2016

BRIEF-Sagent pharmaceuticals initiates voluntary recall of Oxacillin

* Sagent Pharmaceuticals initiates a nationwide voluntary recall of Oxacillin for injection, USP, 10g due to presence of dark particulate matter

Jun 13 2016

BRIEF-Sagent Pharmaceuticals reports Q1 loss per share $0.15

* Sagent Pharmaceuticals reports first quarter 2016 financial results

May 03 2016

Market turmoil drives small biotechs to big pharma

Numerous small biotechnology companies have been all but shut out of the capital markets, leaving many with no choice but to consider a sale to larger peers.

Feb 16 2016

Sagent Pharmaceuticals explores sale: sources

Sagent Pharmaceuticals Inc, a U.S. generic life sciences company focusing on injectable drugs, is considering a sale of the company as part of an exploration of strategic alternatives, according to people familiar with the matter.

Jan 13 2016

Sagent Pharmaceuticals explores sale -sources

Jan 13 Sagent Pharmaceuticals Inc, a U.S. generic life sciences company focusing on injectable drugs, is considering a sale of the company as part of an exploration of strategic alternatives, according to people familiar with the matter.

Jan 13 2016

U.S. RESEARCH ROUNDUP-Apple, Intel, Coca-Cola, Macerich

Jan 12 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Interactive Brokers Group and UDR Inc, on Tuesday. HIGHLIGHTS * Apple : BofA Merrill raises to buy from neutral * Intel Corp : Mizuho Securities raises to buy; raises target price to $37 * Coca-Cola Co : Stifel raises to buy from hold * Interactive Brokers Group Inc : Goldman Sachs cuts to sell from neutral * UDR Inc : Cowen

Jan 12 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.